Oncolytics Biotech, Inc. Common Shares (ONCY) Dividend History

Company News

• New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

  The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.

  Benzinga

  Featured Companies: ACLX AKYA QTRX TCRX
• Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

  Oncolytics Biotech reported positive clinical results for its lead drug candidate pelareorep in various cancer types, including anal and pancreatic cancers. The company also highlighted upcoming milestones and financial results for the first quarter of 2025.

  Benzinga
• Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

  Oncolytics Biotech, a clinical-stage biotechnology company, will host a conference call to discuss its first quarter 2025 financial results and recent operational highlights.

  Benzinga
• New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

  The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.

  Benzinga

  Featured Companies: BCTX STRO TEM
• Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

  The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

  Benzinga

  Featured Companies: ALXO CRDF EXEL VSTM